{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"8.1","value":"2.3"},{"groupId":"OG001","lowerLimit":"2.1","upperLimit":"18.9","value":"4.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"description":"PFS is defined as the time from first day of study treatment to the first documented disease progression or death due to any cause, whichever occurs first. Progressive Disease: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions was also considered progression). PFS was summarized by Kaplan-Meier (KM) methods. The data cutoff date was 19-FEB-2021.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan. Cohort A participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to approximately 35 cycles (up to approximately 2 years).","id":"OG000","title":"Cohort A - Pembrolizumab 200 mg"},{"description":"Participants were previously treated with at least one line of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or fluoropyrimidine + irinotecan +/ - anti vascular endothelial growth factor (VEGF)/ epidermal growth factor regulator (EGFR) monoclonal antibody. Cohort B participants received pembrolizumab 200 mg IV on Day 1 Q3W for up to approximately 35 cycles (up to approximately 2 years).","id":"OG001","title":"Cohort B - Pembrolizumab 200 mg"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all participants who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 66 months","title":"Progression-Free Survival (PFS) Per RECIST 1.1 Assessed by Central Imaging Vendor.","type":"SECONDARY","unitOfMeasure":"Months"}